利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

7 条记录 (耗时 0.02 秒)

    Adenovirus 36 E4 orf 1 gene and protein and their uses
    2.
    发明授权
    Adenovirus 36 E4 orf 1 gene and protein and their uses 有权
    腺病毒36 E4 orf 1基因和蛋白质及其用途

    公开(公告)号：US08008436B2

    公开(公告)日：2011-08-30

    申请号：US12095441

    申请日：2006-11-30

    申请人： Nikhil V. Dhurandhar ,  Thomas C. Holland ,  Zhong Q. Wang

    发明人： Nikhil V. Dhurandhar ,  Thomas C. Holland ,  Zhong Q. Wang

    IPC分类号： C07K14/075 ,  A16K48/00

    CPC分类号： A61K48/005 ,  A61K38/00 ,  C07K14/005 ,  C12N2710/10322 ,  C12N2710/10332

    摘要： Expression of the E4 orf 1 gene of Ad-36 alone has been discovered to be responsible for the increased insulin sensitivity observed in Ad-36 infected animals, including increased adipogenesis. Ad-36 E4 orf 1 protein can be used to increase insulin sensitivity and ameliorate diabetes. Additionally, drugs that mimic the action of Ad-36 E4 orf 1 protein could be found. Ad-36 E4 orf 1 could also be used to increase fat cells in lipodystrophy. We have also discovered that Ad-36 infection in human skeletal muscle cells increased differentiation and insulin independent glucose uptake. It is expected that infection with Ad-36 E4 orf 1 gene will also cause these effects.

    摘要翻译： 已经发现Ad-36单独的E4 orf1基因的表达负责在Ad-36感染的动物中观察到的增加的胰岛素敏感性，包括增加的脂肪形成。 Ad-36 E4 orf 1蛋白可用于增加胰岛素敏感性并改善糖尿病。 此外，可以发现模仿Ad-36 E4 orf 1蛋白的作用的药物。 Ad-36 E4 orf 1也可用于增加脂肪营养不良中的脂肪细胞。 我们还发现，人骨骼肌细胞中的Ad-36感染增加分化和胰岛素独立的葡萄糖摄取。 预期Ad-36 E4 orf 1基因的感染也会引起这些影响。

    Anti-aging micrornas
    5.
    发明授权
    Anti-aging micrornas 有权
    抗衰老微棱镜

    公开(公告)号：US08354384B2

    公开(公告)日：2013-01-15

    申请号：US11426292

    申请日：2006-06-23

    申请人： Frank J. Slack ,  Michelle M. Boehm

    发明人： Frank J. Slack ,  Michelle M. Boehm

    IPC分类号： A16K48/00

    CPC分类号： G01N33/502 ,  C12N15/113 ,  C12N2310/111 ,  C12N2310/14 ,  G01N33/6893 ,  G01N2500/00 ,  G01N2800/042

    摘要： Methods and compositions for modulating aging genes or their targets for the treatment or prevention of senescence or symptoms thereof have been developed based on the discovery of naturally occurring inhibitory nucleic acids, in particular lin-4 miRNA, that downregulate genes involved in senescence, lifespan, or age-related disorders. Representative aging genes include, but are not limited to lin-4, lin-14, let-7, lin-28, egl-35 and lin-42. Methods for identifying modulators of aging genes and targets of aging genes are also provided. The disclosed compositions are useful as diagnostics. These can be used in assays to compare genes in normal individuals, with those who are aging well or who demonstrate early senescence, and with those who have age-related disorders such as Parkinson's and Alzheimer's. The genes can be used to study the pathways and mechanisms involved in aging and age-related disorders. These genes can be used as drug targets, or in drug design, to develop drugs that can inhibit one or more characteristics of senescence or age-related disorders. These compositions should be effective therapies for treating or slowing the effects of one or more symptoms or characteristics of age-related disorders resulting from activation or over-expression of aging genes. Compositions that alter the expression of particular aging genes affecting the insulin-like signal pathway are described. Suitable compositions described herein include, inhibitory nucleic acids and small molecules, in particular miRNA.

    摘要翻译： 基于天然存在的抑制性核酸特别是lin-4 miRNA的发现，已经开发了用于调节衰老基因或其靶向治疗或预防衰老或其症状的方法和组合物，其下调参与衰老，寿命， 或年龄相关疾病。 代表性的老化基因包括但不限于lin-4，lin-14，let-7，lin-28，egl-35和lin-42。 还提供了用于鉴定老化基因调节剂和老化基因靶标的方法。 所公开的组合物可用作诊断。 这些可以用于比较正常个体的基因，老年人或早期衰老的基因，以及与年龄相关的疾病如帕金森病和阿尔茨海默氏症的患者。 这些基因可用于研究衰老和年龄相关疾病所涉及的途径和机制。 这些基因可以用作药物靶点，或在药物设计中用于开发能够抑制衰老或年龄相关疾病的一个或多个特征的药物。 这些组合物应该是治疗或减缓由老化基因的激活或过度表达引起的一种或多种症状或年龄相关疾病特征的影响的有效疗法。 描述了改变影响胰岛素样信号通路的特定老化基因表达的组合物。 本文所述的合适的组合物包括抑制性核酸和小分子，特别是miRNA。

    Cancer treatment by combined inhibition of proteasome and telomerase activities
    6.
    发明授权
    Cancer treatment by combined inhibition of proteasome and telomerase activities 有权
    癌症治疗联合抑制蛋白酶体和端粒酶活性

    公开(公告)号：US07998938B2

    公开(公告)日：2011-08-16

    申请号：US11918581

    申请日：2006-04-14

    申请人： Malcolm A.S. Moore ,  Allison C. Chin

    发明人： Malcolm A.S. Moore ,  Allison C. Chin

    IPC分类号： A16K48/00

    CPC分类号： C12N15/1137 ,  A61K31/454 ,  A61K45/06 ,  C12N2310/11 ,  C12N2310/3145 ,  C12N2310/3515 ,  C12Y207/07049 ,  A61K2300/00

    摘要： A method and kit for inhibiting the proliferation of cancer cells are disclosed, based on a combination of a proteasome inhibitor and a telomerase inhibitor. When used in cancer therapy, the two compounds in combination enhance the anti-cancer treatment efficacy obtained with the proteasome inhibitor alone or the telomerase inhibitor alone. Preferably, efficacy is supraadditive or synergistic in nature relative to the combined effects of the individual agents, with minimal exacerbation of side effects.

    摘要翻译： 基于蛋白酶体抑制剂和端粒酶抑制剂的组合，公开了抑制癌细胞增殖的方法和试剂盒。 当用于癌症治疗时，两种化合物组合增强了单独使用蛋白酶体抑制剂或单独使用端粒酶抑制剂获得的抗癌治疗功效。 优选地，相对于各个试剂的组合效应，效力是相对于辅助的或协同的，并且副作用的加剧最小化。

    Recombinant vector expressing multiple costimulatory molecules and uses thereof
    7.
    发明授权
    Recombinant vector expressing multiple costimulatory molecules and uses thereof 有权
    表达多种共刺激分子的重组载体及其用途

    公开(公告)号：US06969609B1

    公开(公告)日：2005-11-29

    申请号：US09856988

    申请日：1999-11-12

    申请人： Jeffrey Schlom ,  James Hodge ,  Dennis Panicali

    发明人： Jeffrey Schlom ,  James Hodge ,  Dennis Panicali

    IPC分类号： A61K35/12 ,  A61K39/00 ,  A61K48/00 ,  C07K14/705 ,  C12N15/863 ,  C12N5/10 ,  C12N5/16 ,  C12N5/22 ,  C12N15/85 ,  A16K48/00

    CPC分类号： C12N15/86 ,  A61K35/12 ,  A61K39/00 ,  A61K48/00 ,  A61K2039/57 ,  C07K14/70503 ,  C07K14/70525 ,  C07K14/70528 ,  C07K14/70532 ,  C12N2710/24043 ,  C12N2710/24143 ,  Y02A50/41 ,  Y02A50/412 ,  Y02A50/464 ,  Y02A50/478

    摘要： The present invention is a recombinant vector encoding and expressing at least three or more costimulatory molecules. The recombinant vector may additionally contain a gene encoding one or more target antigens or immunological epitope thereof. The synergistic effect of them costimulatory molecules on the enhanced activation of T cells is demonstrated. The degree of T-cell activation using recombinant vectors containing genes encoding three costimulatory molecules was far greater than the sum of recombinant vector constructs containing one costimulatory molecule and greater that the use of two costimulatory molecules. Results employing the triple costimulatory vectors were most dramatic under conditions of either low levels of first signal or low stimulator to T-cell ratios. This phenomenon was observed with both isolated CD4+and CD8+T cells. The recombinant vectors of the present invention are useful as immunogenes and vaccines against cancer and pathogenic micro-organisms, and in providing host cells, including dendritic cells and splenocytes with enhanced and antigen-presenting functions.

    摘要翻译： 本发明是编码并表达至少三种或更多共刺激分子的重组载体。 重组载体可另外含有编码一种或多种靶抗原或其免疫表位的基因。 证明了它们共刺激分子对增强的T细胞活化的协同作用。 使用含有编码三个共刺激分子的基因的重组载体的T细胞活化程度远远大于含有一个共刺激分子的重组载体构建物的总和，并且使用两个共刺激分子更大。 使用三重共刺激载体的结果在低水平的第一信号或低刺激剂与T细胞比率的条件下最显着。 在分离的CD4 +和/或CD8 + T细胞中都观察到这种现象。 本发明的重组载体可用作抗癌和致病微生物的免疫原和疫苗，并且提供宿主细胞，包括具有增强和抗原呈递功能的树突状细胞和脾细胞。